Delivery Order 75N93022D00004-75N93024F00001
Award Date 8/31/24
Potential Completion Date 8/27/28
Potential Value $3.8M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Rockville, MD 20850, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award, valued at $2,959,434.41, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The contract is for the synthesis and production of an HIV-1 envelope glycopeptide immunogen nanoparticle vaccine as part of NIAID's Preclinical Development Support program. This is a cost-plus-fixed-fee delivery order contract with an ultimate...
- This is a cost-plus-fixed-fee delivery order contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL) for long-term stability testing of a nanoparticle-based HIV envelope vaccine. The $625,721 contract has a completion date of June 9, 2029 and is not associated with a set-aside program. ABL is a leading contract research and manufacturing organization specializing in biologics...
- This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL), a contract research and manufacturing organization. The $3,150,428.64 award is a delivery order under the HIV Microbicides and Biomedical Prevention 2016-2021 indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. ABL will provide comprehensive resources for HIV...
- This is a $3,017,609 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL) for fill-finish, release, and stability testing of HIV-1 gp120 proteins. The contract has an ultimate completion date of April 15, 2025. ABL is a for-profit organization that specializes in the development of biologics, vaccines, and immunotherapies....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order contract to Advanced Bioscience Laboratories, Inc. (ABL) on August 9, 2018, with a ceiling value of $12.9 million for current Good Manufacturing Practice (cGMP) manufacturing of PGT121 and PGDM1400 antibodies in support of preclinical development activities. The contract, which carries a cost-plus-fixed-fee pricing structure with no set-aside designation, is scheduled for completion by December 31, 2031,...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL) for $1,151,180.13. The contract is a delivery order under a larger HIV Microbicides and Biomedical Prevention program that runs from 2016-2021. Under this contract, ABL will perform quality evaluation and certification of a study product to ensure it meets regulatory requirements for use in...
- This is a $6,095,159.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL) for expertise in professional pharmaceutical project management. The contract is issued under the larger Resources to Advance Pediatrics and HIV Prevention Science indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. ABL, a manufacturer of biologics including vaccines and monoclonal antibodies,...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services. The contract, valued at $3,731,476.00, is for the NIAID Preclinical Development Support program, specifically to support the production and testing of ADC6-HIV GP140 and ADC7-HIV GP140. The prime contractor is Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods that specializes in the...
- This federal contract award is to Advanced Bioscience Laboratories, Inc. (ABL) from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services. The contract is for the performance of toxicity testing for HIV proteins as part of NIAID's Preclinical Development Support program. The contract is a cost-plus-fixed-fee delivery order with a ceiling value of $1,050,558.51 and a period of performance through April 7, 2017....
- This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $1,529,440.80 cost-plus-fixed-fee contract provides statistical support for HIV non-vaccine biomedical prevention product development under NIAID's "Comprehensive Resources for HIV Microbicides and Biomedical Prevention"...